CELLDEX THERAPEUTICS INC (CLDX)
US15117B2025 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 4.65M -37.33% | 2.36M -49.25% | 6.883M 191.65% | 6.333M -7.99% | 3.718M -41.29% | 3.841M 3.31% | 36.679M 854.93% | 301.08M 720.85% | 759.43M 152.24% | 1.217B 60.25% | 1.32B 8.46% | |
| EBITDA YoY % growth | -64.67M -56.13% | -97.33M -50.50% | -139.034M -42.85% | -188.047M -35.25% | -237.923M -26.52% | -265.139M -11.44% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -67.74M -49.37% | -100.23M -47.96% | -142.042M -41.72% | -192.328M -35.40% | -235.514M -22.45% | -280.378M -19.05% | -271.754M 3.08% | -114.113M 58.01% | 239.39M 309.78% | 568.14M 137.33% | 972.57M 71.18% | |
| Operating Margin | -1,456.77% | -4,247.03% | -2,063.66% | -3,036.91% | -6,334.43% | -7,299.61% | -740.90% | -37.90% | 31.52% | 46.68% | 73.68% | |
| EPS YoY % growth | -1.64 23.36% | -2.21 -34.76% | -2.91 -31.67% | -2.47 14.98% | -3.30 -33.33% | -3.85 -16.81% | -4.11 -6.68% | -0.56 86.35% | 3.96 805.45% | 8.81 122.55% | 10.21 15.92% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.75 9.82% | -0.83 -48.75% | -0.86 -59.93% | -0.86 -34.41% | -0.89 -19.24% |
| Revenue Q2Q % growth | 1.113M -73.06% | 331.5K 112.50% | 331.5K -86.73% | 331.5K -89.61% | 441.997K -60.29% |
| EBITDA Q2Q % growth | -54.978M -71.17% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -54.183M -54.25% | -58.239M -43.42% | -60.499M -30.62% | -60.729M -16.51% | -64.668M -19.35% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.64 20.99% | -0.69 | 0.05 | 6.71% |
| Q2 2024 Q2Q % growth | -0.54 16.92% | -0.60 | 0.06 | 9.93% |
| Q1 2024 Q2Q % growth | -0.56 9.68% | -0.71 | 0.15 | 20.89% |
| Q4 2023 Q2Q % growth | -0.83 -48.21% | -0.76 | -0.07 | -9.41% |
| Q3 2023 Q2Q % growth | -0.81 -42.11% | -0.69 | -0.12 | -17.03% |
| Q2 2023 Q2Q % growth | -0.65 -10.17% | -0.68 | 0.03 | 4.41% |
| Q1 2023 Q2Q % growth | -0.62 -26.53% | -0.64 | 0.02 | 3.82% |
| Q4 2022 Q2Q % growth | -0.56 -30.23% | -0.60 | 0.04 | 6.95% |
| Q3 2022 Q2Q % growth | -0.57 -26.67% | -0.59 | 0.02 | 3.09% |
| Q2 2022 Q2Q % growth | -0.59 -73.53% | -0.52 | -0.07 | -13.42% |
| Q1 2022 Q2Q % growth | -0.49 -16.67% | -0.46 | -0.03 | -5.81% |
| Q4 2021 Q2Q % growth | -0.43 21.82% | -0.43 | 0.00 | -1.18% |
| Q3 2021 Q2Q % growth | -0.45 -25.00% | -0.37 | -0.08 | -22.55% |
| Q2 2021 Q2Q % growth | -0.34 32.00% | -0.41 | 0.07 | 16.67% |
| Q1 2021 Q2Q % growth | -0.42 42.47% | -0.39 | -0.03 | -8.36% |
| Q4 2020 Q2Q % growth | -0.55 14.06% | -0.37 | -0.18 | -47.06% |
| Q3 2020 Q2Q % growth | -0.36 52.00% | -0.37 | 0.01 | 1.96% |
| Q2 2020 Q2Q % growth | -0.50 40.48% | -0.59 | 0.09 | 15.48% |
| Q1 2020 Q2Q % growth | -0.73 47.86% | -0.72 | -0.01 | -0.80% |
| Q4 2019 Q2Q % growth | -0.64 20.99% | -0.92 | 0.28 | 30.28% |
| Q3 2019 Q2Q % growth | -0.75 -25.00% | -0.86 | 0.11 | 12.46% |
| Q2 2019 Q2Q % growth | -0.84 49.09% | -1.19 | 0.35 | 29.61% |
| Q1 2019 Q2Q % growth | -1.40 -55.56% | -1.16 | -0.24 | -20.40% |
| Q4 2018 Q2Q % growth | -0.81 | -1.22 | 0.41 | 33.82% |
| Q3 2018 Q2Q % growth | -0.60 | -2.30 | 1.69 | 73.86% |
| Q2 2018 Q2Q % growth | -1.65 | -2.14 | 0.49 | 22.97% |
| Q1 2018 Q2Q % growth | -0.90 | -3.09 | 2.19 | 70.88% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 3.191M 110.35% | 844.866K | 2.346M | 277.69% |
| Q2 2024 Q2Q % growth | 2.498M 832.09% | 836.839K | 1.661M | 198.50% |
| Q1 2024 Q2Q % growth | 156K -83.87% | 934.065K | -778.065K | -83.30% |
| Q4 2023 Q2Q % growth | 4.132M 156.65% | 859.717K | 3.272M | 380.62% |
| Q3 2023 Q2Q % growth | 1.517M 270.00% | 586.837K | 930.163K | 158.50% |
| Q2 2023 Q2Q % growth | 268K 67.50% | 538.56K | -270.56K | -50.24% |
| Q1 2023 Q2Q % growth | 967K 468.82% | 418.2K | 548.8K | 131.23% |
| Q4 2022 Q2Q % growth | 1.61M 387.88% | 269.28K | 1.341M | 497.89% |
| Q3 2022 Q2Q % growth | 410K 173.33% | 367.2K | 42.8K | 11.66% |
| Q2 2022 Q2Q % growth | 160K -95.40% | 408K | -248K | -60.78% |
| Q1 2022 Q2Q % growth | 170K -75.36% | 571.2K | -401.2K | -70.24% |
| Q4 2021 Q2Q % growth | 330K -91.29% | 1.057M | -727K | -68.78% |
| Q3 2021 Q2Q % growth | 150K -77.61% | 1.246M | -1.096M | -87.96% |
| Q2 2021 Q2Q % growth | 3.48M 1,350.00% | 656.197K | 2.824M | 430.33% |
| Q1 2021 Q2Q % growth | 690K -74.73% | 816K | -126K | -15.44% |
| Q4 2020 Q2Q % growth | 3.79M 325.84% | 612K | 3.178M | 519.28% |
| Q3 2020 Q2Q % growth | 670K 21.82% | 402.9K | 267.1K | 66.29% |
| Q2 2020 Q2Q % growth | 240K -66.67% | 816K | -576K | -70.59% |
| Q1 2020 Q2Q % growth | 2.73M 90.91% | 1.01M | 1.72M | 170.30% |
| Q4 2019 Q2Q % growth | 890K -49.43% | 831.3K | 58.7K | 7.06% |
| Q3 2019 Q2Q % growth | 550K -41.49% | 1.285M | -735K | -57.20% |
| Q2 2019 Q2Q % growth | 720K -73.91% | 1.285M | -565K | -43.97% |
| Q1 2019 Q2Q % growth | 1.43M -64.86% | 1.255M | 175K | 13.94% |
| Q4 2018 Q2Q % growth | 1.76M | 1.489M | 271K | 18.20% |
| Q3 2018 Q2Q % growth | 940K | 1.928M | -988K | -51.24% |
| Q2 2018 Q2Q % growth | 2.76M | 2.343M | 417K | 17.80% |
| Q1 2018 Q2Q % growth | 4.07M | 2.354M | 1.716M | 72.90% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0.74% | 2.68% | 1.37% | 1.71% |
| Revenue | 26.69% | 15.99% | 13.07% | 52.35% |